Work

Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.7050

Authors: Martin Mueller, Michele Baccarani, Michael W.N. Deininger, Francois Guilhot, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Stephanie Lustgarten, Sergio Santillana, Victor M Rivera, Timothy Piers Clackson, Jorge E. Cortes

Institutions: University of Bologna, Huntsman Cancer Institute, Inserm, Centre Hospitalier Universitaire de Poitiers, Jena University Hospital, South Australian Health and Medical Research Institute, The University of Adelaide, University of California, San Francisco, University of Michigan, U-M Rogel Cancer Center, ARIAD Pharmaceuticals (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890670704

Cites:

Cited by: 2

Related to: 10